Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1 (AcSé)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02034981 |
Recruitment Status :
Completed
First Posted : January 14, 2014
Last Update Posted : February 28, 2024
|
Sponsor:
UNICANCER
Collaborators:
National Cancer Institute, France
Fondation ARC
Pfizer
Information provided by (Responsible Party):
UNICANCER
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Completed |
---|---|
Actual Primary Completion Date : | June 2019 |
Actual Study Completion Date : | December 6, 2023 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):